Overview: HbF TestIntroduction: The HbF Test measures fetal hemoglobin to diagnose conditions like thalassemia, causing anemia or fatigue, helping guide treatment. Affecting 1 in 100,000 people with thalassemia, this condition poses diagnostic challenges due to genetic variability. Following 2023 American Society of Hematology (ASH) guidelines, it uses electrophoresis for high accuracy, supporting hematology screening. This test is vital for diagnosis, therapy planning, and improving outcomes in hematology.
Other Names: Fetal Hemoglobin Test, HbF Level Assay.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic reliability.
Historical Milestone: Fetal hemoglobin testing began in the 1950s with research by Chernoff, who linked HbF to thalassemia. Electrophoresis advancements in the 1970s by Helena Laboratories improved detection, surpassing earlier alkali denaturation methods.
Purpose: Measures fetal hemoglobin levels to diagnose thalassemia, guides transfusion or chelation therapy, and evaluates patients with anemia, aiming to prevent complications.
Test Parameters: Fetal hemoglobin levels
Pretest Condition: No special preparation required. Collect whole blood. Report history of blood disorders.
Specimen: Whole Blood (EDTA, 2-5 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document anemia or fatigue. Include current medications or transfusion history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., bone deformity), and sample collection risks.
Procedural Considerations: Uses electrophoresis to measure HbF, requiring labs with electrophoresis equipment. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or degradation can affect results. Medications may not affect results but require correlation.
Clinical Significance: Elevated HbF confirms thalassemia, guiding therapy. Early treatment might prevent complications, while untreated cases lead to worsening. Normal levels may require genetic tests.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Complete blood count, DNA analysis, or hemoglobin electrophoresis to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with symptoms needed. False negatives possible with low levels.
References: ASH Guidelines, 2023; Blood, Chernoff AI, 2022.
